NCT05301010View on ClinicalTrials.gov

Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

February 2, 2018

Primary Completion Date

February 19, 2021

Study Completion Date

February 19, 2021

Conditions
Breast Cancer MetastaticBreast Cancer RecurrentBreast Cancer Female
Interventions
DRUG

Faceptor

NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.

DRUG

Herceptin

Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.

DRUG

Docetaxel

The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.

Trial Locations (2)

Unknown

19-8 Hospital, Hanoi

HCMC Oncology Hospital, Ho Chi Minh City

Sponsors
All Listed Sponsors
collaborator

Vietstar Biomedical Research

INDUSTRY

collaborator

MedProve Inc

UNKNOWN

lead

Nanogen Pharmaceutical Biotechnology Joint Stock Company

INDUSTRY